%0 Journal Article %T Effects of dexamethasone on immune dysfunction and ventilator-associated pneumonia in COVID-19 acute respiratory distress syndrome: an observational study %+ Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN) %+ Hôpital Edouard Herriot [CHU - HCL] %+ Université Claude Bernard Lyon 1 (UCBL) %+ Centre International de Recherche en Infectiologie (CIRI) %A Cour, M. %A Simon, M. %A Argaud, L. %A Monneret, G. %A Venet, F. %< avec comité de lecture %@ 2052-0492 %J Journal of Intensive Care %I BioMed Central %V 9 %N 1 %P 64 %8 2021 %D 2021 %R 10.1186/s40560-021-00580-6 %M 34663481 %K CD4 + lymphocyte %K Intensive care unit %K Monocyte HLA-DR %K Nosocomial infection %K SARS-CoV-2 %Z Life Sciences [q-bio]Journal articles %X Dexamethasone improves survival of patients with COVID-19 acute respiratory distress syndrome, but might shorten the delay between the start of invasive mechanical ventilation and the occurrence of ventilator-associated pneumonia, suggesting possible worsening of COVID-19-induced immune dysfunction with this treatment. In a prospective observational study, we found that mechanically ventilated patients with COVID-19 treated with dexamethasone presented earlier ventilator-associated pneumonia, had significantly lower monocyte Human Leukocyte Antigen-DR expression and number of circulating CD4 + cells after ICU admission, than those not treated with corticoids. %G English %2 https://inserm.hal.science/inserm-03753365/document %2 https://inserm.hal.science/inserm-03753365/file/s40560-021-00580-6.pdf %L inserm-03753365 %U https://inserm.hal.science/inserm-03753365 %~ INSERM %~ UNIV-ST-ETIENNE %~ ENS-LYON %~ HCL %~ CNRS %~ UNIV-LYON1 %~ HEH %~ CARMEN %~ CIRI %~ UDL %~ UNIV-LYON %~ INRAE %~ TEST3-HALCNRS